Venous Thromboembolism (VTE)

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

BEVYXXAApproved

betrixaban

Unknown Company

oral2017

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AstraZenecaCAMBRIDGE, United Kingdom

1 program

BetrixabanPhase 31 trial

Active Trials

NCT01583218Completed7,513Est. Jan 2016

Ribocure PharmaceuticalsSweden - Mölndal

1 program

VortosiranPhase 22 trials

Active Trials

NCT07870889Not Yet Recruiting150Est. Aug 2028

NCT07850453Not Yet Recruiting150Est. May 2028

Daiichi SankyoChina - Shanghai

2 programs

EdoxabanPHASE_31 trial

Active Trials

NCT02798471Completed290Est. May 2022

NCT02073682Completed1,046Est. Sep 2017

Vera TherapeuticsBRISBANE, CA

1 program

Experimental: HyperslimPHASE_41 trial

Active Trials

NCT06958588RecruitingEst. Mar 2026

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

Vera TherapeuticsExperimental: Hyperslim

Daiichi SankyoEdoxaban

AstraZenecaBetrixaban

Ribocure PharmaceuticalsVortosiran

Clinical Trials (6)

Total enrollment: 9,149 patients across 6 trials

NCT06958588 Vera TherapeuticsExperimental: Hyperslim

Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis

Start: May 2025Est. completion: Mar 2026

Phase 4Recruiting

NCT02798471 Daiichi SankyoEdoxaban

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Start: Mar 2017Est. completion: May 2022290 patients

Phase 3Completed

NCT02073682 Daiichi SankyoEdoxaban

Cancer Venous Thromboembolism (VTE)

Start: Jul 2015Est. completion: Sep 20171,046 patients

Phase 3Completed

NCT01583218 AstraZenecaBetrixaban

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Start: Mar 2012Est. completion: Jan 20167,513 patients

Phase 3Completed

NCT07870889 Ribocure PharmaceuticalsVortosiran

Vortosiran in Atrial Fibrillation

Start: Oct 2026Est. completion: Aug 2028150 patients

Phase 2Not Yet Recruiting

NCT07850453 Ribocure PharmaceuticalsVortosiran

Vortosiran for VTE Prevention

Start: Oct 2026Est. completion: May 2028150 patients

Phase 2Not Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 9,149 patients

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.